Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 8/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.65 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.65 |
| ▸ | RAF1 | P04049 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.63 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731983 | 0.87 | KDR (0.61) | MAPK10MAPK8MAPK9RAF1LCK | |
| Hydrochloric Acid SCHEMBL3737793 | 0.86 | KDR (0.60) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL4276210 | 0.86 | KDR (0.60) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL4847094 | 0.83 | KDR (0.65) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL635132 | 0.82 | MAPK10 (0.47) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL5796355 | 0.82 | KDR (0.56) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL4844255 | 0.82 | KDR (0.66) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL4851040 | 0.81 | KDR (0.61) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL4844219 | 0.81 | KDR (0.64) | MAPK10MAPK8MAPK9RAF1LCK | |
| SCHEMBL4848688 | 0.81 | KDR (0.58) | MAPK10MAPK8MAPK9RAF1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829717-B2 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7618965-B2 | N-(3-{[1-(dimethylamino)-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide; neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma | OSI PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618965-B2 | N-(3-{[1-(dimethylamino)-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide; neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma | OSI PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618965-B2 | N-(3-{[1-(dimethylamino)-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide; neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma | OSI PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7439256-B2 | (Arylamidoaryl) cyanoguanidine compounds | OSI PHARMACEUTICALS, INC. | 2008-10-21 | — | — | US | disclosed |
| US-7439256-B2 | (Arylamidoaryl) cyanoguanidine compounds | OSI PHARMACEUTICALS, INC. | 2008-10-21 | — | — | US | disclosed |
| US-7439256-B2 | (Arylamidoaryl) cyanoguanidine compounds | OSI PHARMACEUTICALS, INC. | 2008-10-21 | — | — | US | disclosed |
| US-7388012-B2 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060111349-A1 | (Arylamidoaryl)squaramide compounds | OSI PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20060074082-A1 | (Arylamidoaryl)cyanoguanidine compounds | OSI PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| US-20060069121-A1 | (Arylamidoanilino)nitroethylene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-30 | — | — | US | disclosed |
| WO-2006034111-A1 | (ARYLAMIDOARYL)SQUARAMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034015-A1 | (SPIROCYCLYLAMIDO) AMINOTHIOPHENE COMPOUNDS AS C-KIT PROTO- ONCOGENE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034075-A1 | (HYDRAZIDO) (AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034110-A1 | (ARYLAMIDOARYL) CYANOGUANIDINE COMPOUNDS AS INHIBITORS OF C-KIT PROTO-ONCOGENE | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034016-A1 | (ARYLAMIDOANILINO) NITROETHYLENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063773-A1 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069121-A1 | (Arylamidoanilino)nitroethylene compounds | KIT, TPSG1, BRCA1 | MAPK10 1144/4885MAPK8 2413/4885MAPK9 1073/4885 |
| US-20060074082-A1 | (Arylamidoaryl)cyanoguanidine compounds | NQO2, NRAS, Q6ZSR9 | MAPK10 832/4885MAPK8 1030/4885MAPK9 39/4885 |
| US-20060111349-A1 | (Arylamidoaryl)squaramide compounds | KIT, TSSK6, MCTS1 | MAPK10 2037/4885MAPK8 2706/4885MAPK9 1673/4885 |
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | KIT, BRDT, MALT1 | MAPK10 1848/4885MAPK8 3811/4885MAPK9 2201/4885 |
| US-20060063773-A1 | (Hydrazido)(amino)thiophene compounds | KIT, BRDT, BRCA1 | MAPK10 2041/4885MAPK8 3134/4885MAPK9 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.